C12N2500/46

Improved method for ex vivo expansion CD34+HSPCs into NK cells using an aryl hydrocarbon receptor antagonist
20180237749 · 2018-08-23 · ·

The present invention relates to the field of medicine, specifically the field of treatment of cancer. More specifically, the invention relates to a method for the ex vivo production of a population of highly functional NK cells from CD34-positive cells, to a population of highly functional NK cells obtained and to the use of such population of highly functional NK cells for adoptive cell therapy.

NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL

Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.

SMAC Mimetic

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

STORAGE METHOD AND BANKING SYSTEM OF NT CELL

Provided are a storage method and a banking system of cells prepared using somatic cell nuclear transfer (NT) technology with homozygous genotypes of genes of human leukocyte antigen (HLA)-A, HLA-B, HLA-DR, and the like. The banking of NT cell-derived stem cells may be applied to autologous or allogenic patients and can provide transplantable cells and tissue materials for the treatment of various diseases such as diabetes, osteoarthritis, Parkinson's disease, and the like.

Serum-free media for producing adipocytes for animal consumption

The invention provides inter alia a method for differentiating an adipogenic progenitor cell. comprising the step of:culturing an adipogenic progenitor cell in a serum-free medium for differentiating an adipogenic progenitor cell. wherein the serum-free medium comprises:at least one peroxisome proliferator-activated receptor gamma (PPARy) agonist:at least one hormone selected from the group consisting of insulin and hydrocortisone:at least one cytokine and/or growth factor selected from the group consisting of bone morphogenetic protein 4 (BMP4) and epidermal growth factor (EGF); and-ascorbic acid or a derivative thereof.

Cell culture compositions with antioxidants and methods for polypeptide production

Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.

DIFFERENTIATING INDUCED PLURIPOTENT STEM CELLS INTO GLUCOSE-RESPONSIVE, INSULIN-SECRETING PROGENY

This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided.

Recombinant cell clones having increased stability and methods of making and using the same

Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.

DEEP EUTECTIC SOLVENTS AND/OR IONIC LIQUIDS IN CELL CULTURE MEDIA

The present invention relates to cell culture media compositions comprising deep eutectic solvents and/or ionic liquids.

Methods and compositions related to Th-1 dendritic cells

Certain embodiments of the invention are directed to methods for inducing an immunologic response to a tumor in a patient using mature dendritic cells transfected with a nucleic acid composition encoding one or more tumor antigens and loaded with a corresponding tumor antigen composition.